

Phone: (949) 645-2111
Fax: (949) 553-1231
Email: bmra@biomerica.com
www.biomerica.com

17571 Von Karman Avenue Irvine, CA 92614 USA

CONFIRMATION

Date: 16th February 2021

To Whom It May Concern:

We, Biomerica, Inc., an EN ISO 13485:2016 certified company specializing in the research, development and manufacturing of in vitro diagnostic products for clinical and research application, located at 17571 Von Karman Avenue, Irvine, CA 92614 USA, hereby confirm that the Biomerica COVID-19 IgG/IgM Rapid Test is based on the Nucleocapsid Protein (N), hence reliably detecting antibodies directed towards the N Protein in patients' samples while the currently reported genetic variations mostly affect the Spike Protein (S). Since our test detects antibodies against a highly conserved portion of the Nucleocapsid Protein, it will not be affected by any mutations to the Spike Protein.

Ry and on hehalf of

5 1 2e

Europe & South America Biomerica, Inc.

